MedPath

UCB CELLTECH

🇬🇧United Kingdom
Ownership
Subsidiary
Established
1925-01-01
Employees
11
Market Cap
-
Website
http://www.ucb.com/worldwide/uk

Clinical Trials

8

Active:0
Completed:6

Trial Phases

2 Phases

Phase 1:5
Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials

Phase 1
5 (62.5%)
Phase 2
3 (37.5%)

A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2021-08-31
Last Posted Date
2021-08-31
Lead Sponsor
UCB Celltech
Target Recruit Count
12
Registration Number
NCT05028127

UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome

Phase 2
Terminated
Conditions
Primary Sjögren's Syndrome
Interventions
Drug: Placebo
First Posted Date
2015-11-20
Last Posted Date
2020-12-01
Lead Sponsor
UCB Celltech
Target Recruit Count
27
Registration Number
NCT02610543
Locations
🇫🇷

Ss0004 34, Brest, France

🇫🇷

Ss0004 30, Le Kremlin-Bicêtre, France

🇫🇷

Ss0004 35, Strasbourg, France

and more 11 locations

A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of UCB4940 in Patients With Psoriasis

Phase 1
Completed
Conditions
Mild to Moderate Psoriasis
Interventions
Other: Placebo
First Posted Date
2015-08-20
Last Posted Date
2015-08-20
Lead Sponsor
UCB Celltech
Target Recruit Count
39
Registration Number
NCT02529956
Locations
🇬🇧

1, Harrow, United Kingdom

Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis

Phase 2
Completed
Conditions
Rheumatoid Arthritis
First Posted Date
2015-04-30
Last Posted Date
2017-05-31
Lead Sponsor
UCB Celltech
Target Recruit Count
159
Registration Number
NCT02430909
Locations
🇨🇿

Ra0123 101, Praha 7, Czechia

🇭🇺

Ra0123 203, Balatonfured, Hungary

🇭🇺

Ra0123 201, Budapest, Hungary

and more 18 locations

A First-In-Human Study With a Single Dose UCB7665 in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
First Posted Date
2014-08-19
Last Posted Date
2015-10-05
Lead Sponsor
UCB Celltech
Target Recruit Count
41
Registration Number
NCT02220153
Locations
🇬🇧

001, Harrow, Middlesex, United Kingdom

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.